EP
DYN icon

Essential Partners’s Dyne Therapeutics DYN Stock Holding History

Essential Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24K Sell
56
-389
-87% -$7.23K ﹤0.01% 2148
2026
Q1 		$8.07K Hold
445
– – ﹤0.01% 1348
2025
Q4 		$8.7K Buy
445
+6
+1% +$114 ﹤0.01% 1212
2025
Q3 		$5.55K Buy
439
+296
+207% +$3.38K ﹤0.01% 1381
2025
Q2 		$1.36K Buy
+143
New +$1.57K ﹤0.01% 1427

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Essential Partners's DYN Position: Q2 2026 in Review

Essential Partners reduced its Dyne Therapeutics (DYN) stake by 87% in Q2 2026, selling an estimated $7.23K and leaving 56 shares worth $1.24K. The position accounts for ﹤0.01% of the portfolio, ranked #2148.

Essential Partners first reported a position in DYN in Q2 2025 and has held it in 5 quarters since. The position peaked at $8.7K in Q4 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Essential Partners held 56 shares of Dyne Therapeutics worth $1.24K as of Q2 2026.
  • Essential Partners sold 389 Dyne Therapeutics shares in Q2 2026, an estimated $7.23K.
  • Dyne Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2148 holding.
  • Essential Partners first reported a position in Dyne Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Dyne Therapeutics position peaked at $8.7K in Q4 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.